Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8734433 | 1.00 | KIF11 (0.44) | KIF11KCNH2KDM4EALOX15TDP1 | |
| SCHEMBL7747362 | 1.00 | KIF11 (0.44) | KIF11KCNH2KDM4EALOX15TDP1 | |
| SCHEMBL8403280 | 0.88 | KIF11 (0.48) | KIF11KCNH2LMNAHTTSMN1; SMN2 | |
| SCHEMBL5023008 | 0.88 | KIF11 (0.56) | KIF11KCNH2 | |
| SCHEMBL11290864 | 0.87 | KDM4E (0.33) | KIF11KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL5065127 | 0.84 | KIF11 (0.45) | KIF11KCNH2LMNAHTTSMN1; SMN2 | |
| SCHEMBL3496480 | 0.82 | KIF11 (0.54) | KIF11KCNH2LMNAHTTSMN1; SMN2 | |
| SCHEMBL10586379 | 0.81 | KIF11 (0.54) | KIF11KCNH2SMN1; SMN2 | |
| SCHEMBL8734430 | 0.81 | NR3C2 (0.37) | KDM4ELMNAHTTSMN1; SMN2KMT2A | |
| SCHEMBL8080069 | 0.79 | KIF11 (0.51) | KIF11KCNH2HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182980-A1 | Reactive Functional Groups | THIRD WAVE TECHNOLOGIES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-7297780-B2 | Reactive functional groups for preparation of modified nucleic acid | THIRD WAVE TECHNOLOGIES, INC. | 2007-11-20 | — | — | US | disclosed |
| US-20040219576-A1 | Reactive functional groups | THIRD WAVE TECHNOLOGIES, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182980-A1 | Reactive Functional Groups | POLRMT, RNGTT, APEX1 | KIF11 2865/4885KCNH2 3861/4885KDM4E 2106/4885 |
| US-20040219576-A1 | Reactive functional groups | POLRMT, RNGTT, APEX1 | KIF11 2865/4885KCNH2 3861/4885KDM4E 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.